- ►annals.org [PDF] JM Kremer, MC Genovese, GW Cannon, JR … - Annals of internal medicine, 2002 - Am Coll Physicians Joel M. Kremer, MD; Mark C. Genovese, MD; Grant W. Cannon, MD; Jacques R.
Caldwell, MD; John J. Cush, MD; Daniel E. Furst, MD; Michael E. Luggen, MD; Ed
Keystone, MD; Michael H. Weisman, MD; William M. Bensen, MD; Jeffrey L. ... Cited by 206 - Related articles - BL Direct - All 4 versions
ME Weinblatt, JM Kremer, JS Coblyn, AL … - Arthritis Care & Research - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 221 - Related articles - BL Direct - All 3 versions
JR O'Dell, R Leff, G Paulsen, C Haire, J … - Arthritis Care & Research - interscience.wiley.com RA patients (n = 171) who had not previously been treated with combinations of
the study medications were randomized to receive 1 of the 3 treatment
combinations in this 2-year, double-blind, placebo-controlled protocol. HCQ ... Cited by 185 - Related articles - BL Direct - All 4 versions
V Strand, S Cohen, M Schiff, A Weaver, R … - Archives of internal medicine, 1999 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Context Leflunomide is a ... Cited by 479 - Related articles - BL Direct - All 5 versions
A Pharmaceuticals - Arthritis Care & Research - interscience.wiley.com Three 6-12-month, double-blind, randomized, controlled trials have shown
leflunomide (LEF; 20 mg/day, loading dose 100 mg × 3 days) to be effective and
safe for the treatment of rheumatoid arthritis (RA). This analysis of the ... Cited by 172 - Related articles - BL Direct - All 4 versions
- ►jrheum.com [PDF] J Kremer, M Genovese, GW Cannon, J Caldwell … - J Rheumatol, 2004 - jrheum.org From the Center for Rheumatology, Albany, New York, USA. Supported by Aventis
Pharmaceuticals. J. Kremer, MD, Center for Rheumatology, Albany, NY; M.
Genovese, MD, Stanford University Medical Center, Stanford, CA; GW Cannon, ... Cited by 43 - Related articles - All 10 versions
P Tugwell, T Pincus, D Yocum, M Stein, O … - New England Journal of Medicine, 1995 - content.nejm.org Results As compared with the placebo group, the patients in the treatment group
had a net improvement in the tender-joint count of 25 percent, or 4.8 joints (95
percent confidence interval, 0.7 to 8.9; P = 0.02), and in the ... Cited by 403 - Related articles - BL Direct - All 5 versions
JR O'Dell, CE Haire, N Erikson, W Drymalski, … - New England Journal of Medicine, 1996 - content.nejm.org Methods We enrolled 102 patients with rheumatoid arthritis and poor responses to
at least one disease-modifying drug in a two-year, double-blind, randomized
study of treatment with methotrexate alone (7.5 to 17.5 mg per week), the ... Cited by 444 - Related articles - BL Direct - All 5 versions
P Emery, FC Breedveld, EM Lemmel, JP … - Rheumatology, 2000 - Br Soc Rheumatology Results. After 1 yr, the mean changes in the leflunomide and methotrexate
groups, respectively, were -8.3 and -9.7 for tender joint count; -6.8 and -9.0
for swollen joint count; -0.9 and -1.2 for physician global assessment; ... Cited by 257 - Related articles - BL Direct - All 5 versions
- ►oxfordjournals.org A Marchesoni, N Battafarano, M Arreghini, B … - Rheumatology, 2003 - Br Soc Rheumatology Methods. In this controlled and randomized single-blind trial, 61 consecutive
patients with untreated RA of less than 2 yr duration were treated with either
CsA + MTX combination therapy (n = 30) or MTX alone (n = 31). The primary ... Cited by 42 - Related articles - BL Direct - All 6 versions
